Institut Curie

The web supplement to
Nabil Amioruchene-Angelozzi et al. 2014


Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
Nabil Amirouchene-Angelozzia 1, Fariba Nematia 1, David Gentiena, André Nicolasb, Amaury Dumontc, Guillaume Caritaa, Jacques Camonisc, Laurence Desjardinsd, Nathalie Cassouxd, Sophie Piperno-Neumanne, Pascale Marianid, Xavier Sastreb, Didier Decaudine 1, Sergio Roman-Romana 1

1Equally contributed.

aTranslational Research Department, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
bDepartment of Tumor Biology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
cINSERM U830, Institut Curie, 26 rue d’Ulm, 75005 Paris , France
dDepartment of Surgical Oncologie, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
eDepartment of Medical Oncology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France


Uveal melanoma (UM) is the most common primary tumor of the eye in adults. There is no standard adjuvant treatment to prevent metastasis and no effective therapy in the metastatic setting. We have established a unique panel of 7 UM cell lines from either patient's tumors or patient-derived tumor xenografts (PDXs). This panel recapitulates the molecular landscape of the disease in terms of genetic alterations and mutations. All the cell lines display GNAQ or GNA11 activating mutations, and importantly four of them display BAP1 (BRCA1 associated protein-1) deficiency, a hallmark of aggressive disease. The mTOR pathway was shown to be activated in most of the cell lines independent of AKT signaling. mTOR inhibitor Everolimus reduced the viability of UM cell lines and significantly delayed tumor growth in 4 PDXs. Our data suggest that mTOR inhibition with Everolimus, possibly in combination with other agents, may be considered as a therapeutic option for the management of uveal melanoma.

Download data:
Raw data (cel files) and reference file (xlsx) Get them (.zip)

Last modified June 19 2014 16:26:16